Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Atezolizumab addition to chemotherapy post-surgery showed no significant improvement in invasive disease-free survival for high-risk TNBC patients. The study reported a higher incidence of severe ...

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

The ZEST trial, a phase 3 study on MRD-guided therapy in breast cancer, was terminated early due to low randomization rates. ctDNA was most frequently detected within six months post-treatment, ...

Friends, have you heard of triple-negative breast cancer [TNBC]? It’s a particularly aggressive type of breast cancer that can grow and spread faster than other types of breast cancer and has a higher ...

From left to right, Dr. Fernando Lecanda, Dr. Karmele Valencia, and Dr. Rafael Martínez Monge, from the Adhesion and Metastasis group at Cima, with Dr. Borja Ruiz-Fernández de Córdoba, also author of ...

SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

Please provide your email address to receive an email when new articles are posted on . A randomized phase 3 trial of minimal residual disease-guided therapy closed early. Future studies should ...

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect ® ...

A new PET radiotracer can effectively visualize Nectin-4, an emerging biomarker found in triple-negative breast cancer (TNBC). According to research published in the March issue of The Journal of ...